Janssen Biotech Inc.
800 Ridgeview Drive
170 articles with Janssen Biotech Inc.
Alligator Bioscience, announces that Janssen Biotech, Inc. will present data from a Phase I clinical study of ADC-1013 at the upcoming ASCO Annual meeting held in Chicago on May 31- June 4.
Protagonist Therapeutics Expands PTG-200 Collaboration Agreement with Janssen to Include Second Generation Oral IL-23 Receptor Antagonists
Protagonist Therapeutics, Inc. announced the expansion of its worldwide license and collaboration agreement with Janssen Biotech, Inc. for the co-development and commercialization of PTG-200, Protagonist's first-in-class, oral peptide IL-23 receptor antagonist, for all indications including inflammatory bowel disease (IBD).
US Bioservices Selected by Janssen as Single-Source Specialty Pharmacy Provider for BALVERSA™ (erdafitinib)
US Bioservices, a specialty pharmacy that is a part of AmerisourceBergen, today announced that it has been selected by Janssen Biotech, Inc. (Janssen) to dispense BALVERSA™ (erdafitinib). Janssen received U.S. Food and Drug Administration (FDA) approval for BALVERSA™ on April 12, 2019
Therapeutic potential of Morphic pipeline expanded by inclusion of both integrin inhibitor and activator research
Waltham, Mass.-based Morphic Therapeutic and Janssen Biotech, a division of Johnson & Johnson, entered into a collaborative deal to develop novel integrin therapeutics for patients with conditions not adequately addressed by current therapies.
Darzalex (daratumumab) for intravenous infusion is approved in the U.S. in combination with bortezomib, melphalan and prednisone for patients with newly diagnosed multiple myeloma (MM) who are ineligible for autologous stem cell transplant.
MorphoSys AG announced today that in its lawsuit against Janssen Biotech and Genmab A/S, the parties have settled the dispute.
Ad hoc: MorphoSys Announces That Its Patents Were Ruled Invalid in Patent Lawsuit Against Janssen and Genmab
MorphoSys AG announces that it was informed that in its lawsuit against Janssen Biotech and Genmab A/S, the United States (U.S.) District Court of Delaware has ruled in a Court Order on January 25, 2019, that the asserted claims of three MorphoSys patents with U.S. Patent Numbers 8,263,746, 9,200,061 and 9,758,590 are invalid.
No financial details of the agreement were released.
YUHAN ANNOUNCES LICENSE AND COLLABORATION AGREEMENT WITH JANSSEN FOR A NOVEL, INVESTIGATIONAL LUNG CANCER THERAPY
Yuhan will receive an upfront payment of $50 million and is eligible to receive up to $1,205 million in potential development and commercial milestone payments, along with tiered double-digit royalties on future net sales.
TESARO, Inc. today announced the achievement of development milestones that trigger an $18 million payment from Janssen Biotech Inc. (Janssen).
10/2/2018Janssen Biotech, a Johnson & Johnson company, informed Aduro Biotech that it was terminating its research and license deals related to Aduro’s Listeria treatment for cancers.
Immune Biosolutions Enters into a Research Collaboration and License Agreement with Johnson & Johnson Innovation to Identify and Develop Therapeutic Antibodies for Multiple Targets
Immune Biosolutions Inc. announced a research collaboration and license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
IGM Biosciences, a privately-held biotech company located in Mountain View, California, announced that Daniel S. Chen will be the company’s new chief medical officer. Chen arrives from Genentech/Roche, where he was most recently vice president, Global Head of Cancer Immunotherapy.
Boston-based Emulate closed on a Series C round worth $36 million.
ViiV Healthcare, established in November 2009 by GlaxoSmithKline, Pfizer and Shiongi, reported positive results from its Phase III GEMINI-1 and -2 clinical trials.
The Janssen Pharmaceutical Companies, part of Johnson & Johnson, announced results from two long-term Phase III trials of esketamine nasal spray.
Halozyme Therapeutics, Inc. will present data evaluating certain biomarkers as potential predictors of survival in patients with previously untreated metastatic pancreatic ductal adenocarcinoma at the American Society of Clinical Oncology annual meeting.
Janssen Biotech, Inc. announced that it has entered into a definitive agreement under which it will acquire BeneVir Biopharm, Inc. (BeneVir), a privately-held, biopharmaceutical company specializing in the development of oncolytic immunotherapies.
Boehringer Ingelheim and OSE Immunotherapeutics signed a collaboration and license deal to jointly develop OSE-172 for myeloid cancers.